Surgical implant company RTI Surgical said Thursday that Camille Farhat has been named chief executive officer, effective March 15. He will succeed interim chief executive officer, Robert P. Jordheim, who will resume his role as chief financial officer.
Farhat, 47, previously served as president and CEO of American Medical Systems, an operating business of Endo International. In this role, he realigned the business to fund innovation, expand internationally and resume growth, ultimately leading to Boston Scientific’s $1.65 billion acquisition of the men’s and prostate health businesses. Farhat’s expertise aligns with RTI’s focus on developing and delivering products for patients and achieving sustainable, long-term growth. He has a track record of revitalizing and profitably growing global businesses within the healthcare industry. Prior to AMS, Farhat held senior leadership roles where he improved the performance of business units at companies including Baxter Healthcare, Medtronic and General Electric.
“Today marks a significant development for RTI’s future. We are pleased that Camille Farhat, an experienced leader with a laser customer focus and solid track record of driving highly effective operational performance in complex health care markets, has agreed to join RTI as our new CEO,” said Curtis M. Selquist, RTI’s chairman. “On behalf of the entire board, I would like to thank Robert Jordheim for his service as interim CEO. We are pleased that he will be returning to his role as our chief financial officer once Camille is on board. I also want to thank Wy Louw, who has been serving as interim CFO and will resume his controller responsibilities.”
Nicholas J. Valeriani, the RTI board member who led the CEO search process, added, “Following a broad search of both internal and external candidates by RTI’s independent directors, we are confident that Camille has the discipline, talent and demonstrated ability to lead RTI to future success. The company and our customers will benefit from his vibrant leadership, dedication to patients, demand for strategic and operational excellence, and persistent dedication to getting things done and achieving sustainable, long-term growth.”
RTI provides surgeons with biologic, metal and synthetic implants.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]